Beyondspring (BYSI) Stock Rating Reaffirmed by Maxim Group

Beyondspring (NASDAQ:BYSI)‘s stock had its “buy” rating restated by analysts at Maxim Group in a research report issued on Wednesday. They presently have a $52.00 target price on the stock. Maxim Group’s price target would indicate a potential upside of 99.92% from the stock’s previous close.

The analysts wrote, “On January 29th, BeyondSpring hosted a KOL call to discuss its lead asset, Plinabulin. Dr. Douglas Blayney, a founding member of the NCCN neutropenia management guideline panel, spoke on the call regarding Plinabulin and the ongoing phase 2/3 trial, Study 105 for the prevention of docetaxel chemotherapy-induced neutropenia (CIN).””

A number of other research analysts have also recently weighed in on the stock. HC Wainwright set a $60.00 target price on shares of Beyondspring and gave the company a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research upgraded shares of Beyondspring from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Seaport Global Securities started coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They issued a “buy” rating and a $56.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Beyondspring presently has a consensus rating of “Buy” and an average price target of $54.50.

Beyondspring (NASDAQ:BYSI) opened at $26.01 on Wednesday. Beyondspring has a 52 week low of $16.55 and a 52 week high of $48.49.

Beyondspring (NASDAQ:BYSI) last released its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.01. sell-side analysts expect that Beyondspring will post -4.41 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Beyondspring stock. Tanaka Capital Management Inc. purchased a new stake in Beyondspring Inc (NASDAQ:BYSI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring accounts for about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned approximately 0.10% of Beyondspring at the end of the most recent quarter. Hedge funds and other institutional investors own 1.22% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at

About Beyondspring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with's FREE daily email newsletter.

Leave a Reply